Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14749299 | 0.81 | GPR119 (0.57) | GPR119PTPN2PTPN1PTPN6NAMPT | |
| SCHEMBL2595242 | 0.78 | GPR119 (0.41) | GPR119PTPN2PTPN1PTPN6MAPT | |
| SCHEMBL28812695 | 0.74 | GPR119 (0.54) | GPR119PTPN2PTPN1PTPN6NAMPT | |
| SCHEMBL3467159 | 0.74 | GPR119 (0.51) | GPR119PTPN2PTPN1PTPN6NAMPT | |
| SCHEMBL9936121 | 0.73 | GPR119 (0.47) | GPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL4900251 | 0.72 | GPR119 (0.49) | GPR119PTPN2PTPN1PTPN6NAMPT | |
| SCHEMBL23119495 | 0.72 | GPR119 (0.59) | GPR119MAPTSMN1; SMN2 | |
| SCHEMBL27599678 | 0.71 | GPR119 (0.55) | GPR119NAMPTMAPTSMN1; SMN2 | |
| SCHEMBL17596554 | 0.71 | RECQL (0.54) | GPR119PTPN2PTPN1PTPN6MAPT | |
| SCHEMBL921685 | 0.71 | GPR119 (0.50) | GPR119PTPN2PTPN1PTPN6NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2566862-B1 | BENZOFURANYL ANALOGUES AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2566862-B1 | BENZOFURANYL ANALOGUES AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | disclosed |
| US-8729084-B2 | Benzofuranyl analogues as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729084-B2 | Benzofuranyl analogues as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729084-B2 | Benzofuranyl analogues as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-20 | — | — | US | disclosed |
| EP-2566862-A1 | BENZOFURANYL ANALOGUES AS GPR119 MODULATORS | Bristol-Myers Squibb Company (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130059858-A1 | BENZOFURANYL ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059858-A1 | BENZOFURANYL ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059858-A1 | BENZOFURANYL ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2011140161-A1 | BENZOFURANYL ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140161-A1 | BENZOFURANYL ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059858-A1 | BENZOFURANYL ANALOGUES AS GPR119 MODULATORS | GPR119, GPR180, GPR139 | GPR119 1/4885PTPN2 2283/4885PTPN1 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.